Overview of Guta

Property	Description
Active ingredient	Zinc Oxide (ZnO)
Form	Topical Preparation (Ointment, Paste)
Pharmacological class	Astringent, Protective Dermatological Agent
Common use	General skin protection and relief of irritation
Origin	Mineral-derived, inorganic compound

What Type of Medicine is Guta?

Guta is fundamentally classified as a non-systemic, protective dermatological agent intended exclusively for external (topical) application. It is a monopreparation that uses a single active substance and belongs to the therapeutic class of astringents.

This drug entity's classification as a protective agent highlights its primary role in providing a physical defense for the skin. Unlike agents designed for systemic absorption or complex pharmacological intervention, Guta operates directly on the surface. Zinc Oxide is recognized as a safe and effective skin protectant, emphasizing its utility in maintaining skin health. Its designation as an astringent means it has the inherent ability to cause a mild contraction and tightening of the skin tissues, a property that contributes to skin stability.

What is the Active Ingredient and Form of Guta?

The sole active pharmaceutical ingredient in Guta is Zinc Oxide (ZnO), a white, mineral-derived, inorganic compound. Guta is typically presented as a dense topical preparation, commonly an ointment, paste, or cream.

The formulation utilizes a very high concentration of Zinc Oxide powder suspended in a hydrophobic fatty vehicle, such as petrolatum or lanolin, to create the final dosage form. This specific high-density form is vital for its purpose, as the heavy, adherent vehicle ensures the formation of a durable, continuous layer that resists moisture and physical displacement. Zinc Oxide's astringent and mild antiseptic properties have made it a staple in topical preparations for centuries, known for its inert nature and protective capabilities.

What is the Overall Purpose of Using Guta?

The overall purpose of Guta is to help prevent mild skin irritation and relieve general discomfort by serving as a durable, physical shield. This protective dermatological agent works by forming a substantial, moisture-repellent mechanical barrier on the skin. Beyond its physical shielding, the Zinc Oxide component imparts a mildly drying effect through its astringent action, which helps to mitigate surface moisture. This dual functionality—protection combined with a minor desiccation—is key to supporting the skin's integrity and providing a soothing sensation, such as in the typical use scenario of protecting skin that is frequently exposed to moisture.

Regulatory References

NIH MedlinePlus

What side effects are possible with Guta?

Possible Side Effects and Safety Information

Guta, often known by its active ingredient glutathione, is generally considered safe when taken orally in appropriate dosages. However, like any supplement, it may cause side effects in some individuals. Most reported side effects are mild and relate to the gastrointestinal system.

Common Side Effects

Side effects that are generally mild and temporary may include:

Gastrointestinal discomfort: This can manifest as bloating, abdominal cramps, nausea, or diarrhea.
Headache
Allergic reactions: Mild symptoms may include rash, itching, or hives.

These issues often resolve as the body adjusts to the supplement or can be managed by adjusting the dosage. Gastrointestinal side effects are often more common with higher doses.

Less Common and Serious Side Effects

While rare, more serious adverse events are possible, particularly with high-dose intravenous administration or in specific populations. If any of the following occur, consult a healthcare professional immediately:

Severe Allergic Reaction (Anaphylaxis): Symptoms requiring emergency attention include difficulty breathing, wheezing, or swelling of the face, lips, or throat.
Worsening of Asthma Symptoms: Inhaled use of glutathione has been linked to potential bronchial spasms in individuals with asthma.
Altered Mineral Levels: Long-term or high-dose use may be associated with reduced levels of essential minerals, such as zinc.
Liver or Kidney Toxicity: Although rare, high doses have raised concerns regarding potential toxic effects on the liver and kidneys, especially with long-term use of injectable forms.

Important Safety Precautions

Consult your doctor before using Guta, especially if you are pregnant, breastfeeding, or have pre-existing medical conditions like asthma or liver/kidney disease. Individuals undergoing chemotherapy should use caution and consult their oncologist, as Guta may theoretically interfere with the effectiveness of certain treatments. Do not exceed the recommended dosage without medical supervision.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for Guta (gepotidacin) provides specific guidance on the documented manifestations of overdose and when emergency medical assistance is mandatory. Overdose or high systemic exposure may result in adverse cardiovascular and neurological effects.

Documented Overdose Presentations

Specific signs of overdose documented in the official labeling include a fast, pounding, or uneven heartbeat, feeling lightheaded or dizzy, or feeling faint or fainting (syncope). The risk of QTc interval prolongation is explicitly noted as a dose- and concentration-dependent concern associated with high systemic exposure.

When to Seek Urgent Help

Immediate medical attention is necessary if severe, life-threatening clinical events occur. Regulatory guidance explicitly mandates calling emergency services (911) if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened (is unresponsive).

For management consultation, official documents advise contacting the Poison Help line (1-800-222-1222) or consulting a medical toxicologist for additional recommendations.

Supportive Management

No specific pharmacologic antidote is documented in the official labeling for Guta overdose. As a result, management is constrained to general symptomatic and supportive treatment, often requiring cardiac monitoring due to the potential for cardiovascular effects. No specific population-based management or severity distinctions are documented in the official overdose section.

Therapeutic Uses of Guta

Quick Facts

Primary Use: Treatment of uncomplicated urinary tract infections (uUTI).
Goal of Therapy: Help resolve infections caused by susceptible bacteria.
Patient Population: Approved for female adults and pediatric patients 12 years of age and older.

Guta, known medically as gepotidacin, is a prescription medication utilized in specific therapeutic domains. The primary role of this medication is in the management of bacterial infections. It is indicated for the treatment of uncomplicated urinary tract infections (uUTI) in female adults and in pediatric patients 12 years of age and older who weigh at least 40 kilograms.

The use of Guta is intended to help resolve infections caused by certain susceptible microorganisms, which may include Escherichia coli and Klebsiella pneumoniae. When a healthcare professional determines that the infection is proven or strongly suspected to be bacterial, this drug may be considered to reduce the impact of the infection. Patient-specific factors and the bacteria's susceptibility pattern should be evaluated before commencing therapy.

Eligibility and Restrictions for Use

The eligibility to use Guta (gepotidacin) is strictly defined by regulatory documents based on demographic and health criteria. The medicine is approved for use in female adults and pediatric patients who are 12 years of age and older and weigh at least 40 kilograms.

Guta is contraindicated and must not be used by patients with a known history of severe hypersensitivity to the drug.

Use is restricted or avoided in specific populations. This includes patients with severe renal impairment (eGFR less than 30 mL/min) and those with severe hepatic impairment (Child-Pugh Class C). The label also advises avoiding use in patients with a history of QTc prolongation or pre-existing cardiac disease, and in those taking strong CYP3A4 inhibitors. Safety and effectiveness have not been established in children younger than 12 years or those weighing less than 40 kg. For pregnancy, official documentation states there are no available data to evaluate drug-associated risk, and a pregnancy exposure registry is established.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Guta (Gepotidacin)

Property	Official Regulatory Statement
Medicinal product categories with documented interactions	Strong CYP3A4 Inhibitors, Strong CYP3A4 Inducers, Drugs that prolong the QTc interval, Acetylcholinesterase Inhibitors.
Specific interacting medicines (if explicitly listed)	Digoxin (P-gp substrate), Itraconazole and Ketoconazole (Strong CYP3A4 Inhibitors).
Mechanistic basis of interactions (only if stated in label)	Gepotidacin is a CYP3A4 substrate. Gepotidacin is a P-gp inhibitor. Gepotidacin possesses acetylcholinesterase inhibitor properties.
Timing-based interaction rules (if applicable)	No mandatory administration time-separation requirements are explicitly listed.
Population-specific interaction notes (if applicable)	Avoid co-administration with Strong CYP3A4 Inhibitors in patients with Severe Hepatic Impairment or Severe Renal Impairment.
Interaction-related restrictions	Co-administration is avoided with Strong CYP3A4 Inhibitors, Strong CYP3A4 Inducers, and Drugs that prolong the QTc interval. Co-administration is avoided with CYP3A4 Substrates with a Narrow Therapeutic Index.

Official Interaction Statements:

Co-administration with Strong CYP3A4 Inhibitors is avoided because it increases gepotidacin systemic exposure, which elevates the risk of QTc prolongation.
Co-administration with Strong CYP3A4 Inducers is avoided because they cause a decrease in gepotidacin exposure.
The official label states that co-administration with Digoxin (a P-gp substrate) may increase digoxin systemic exposures, requiring monitoring of digoxin serum concentrations.
Co-administration with other Drugs that Prolong the QTc Interval is avoided due to the potential for additive QTc prolongation effects.
The drug’s documented acetylcholinesterase inhibitor properties may augment the effects of other acetylcholinesterase inhibitors or Succinylcholine-type Neuromuscular Blocking Agents.

Connection to the overall interaction profile:

Official regulatory documents define the interaction structure of Guta (gepotidacin) by addressing its profile as both a CYP3A4 substrate and a P-gp inhibitor. This metabolic and transporter profile requires specific constraints regarding co-administration with other medicines, ranging from the avoidance of potent enzyme modulators to the requirement for drug level monitoring for sensitive substrates. Pharmacodynamic constraints are further imposed by the documented risk of additive QTc prolongation and interaction with cholinergic agents.

Mechanism of Action

The action of Guta, based on its active ingredient Zinc Oxide, is defined by a primary, dual-action mechanism that is strictly limited to the surface of the skin. This effect is non-systemic, highly localized, and relies on both physical and chemical interactions to modulate the physiological conditions of the local epidermal environment.

Mechanism 1: The Dual Protective and Astringent Action

This domain covers the drug’s primary physical and chemical targets: the Skin Surface and Epidermal Cell Surface Proteins. By establishing a continuous Mechanical Barrier, Guta physically separates the epidermis from external stressors, such as moisture and friction. Concurrently, the slow release of Zn^2+ causes Protein Precipitation, which contracts the superficial tissue and reduces local fluid leakage, initiating a mild drying effect that contributes to the maintenance of the tissue barrier function.

Mechanism 2: Local Modulation of Inflammatory Pathways

This domain focuses on the subtle inhibitory effect of Zn^2+ on cellular signaling, particularly the NF-kappa B pathway, which regulates local inflammation. This mechanism functions to modulate the transcription of pro-inflammatory mediators and influence the local tissue environment. This pathway modulation results in an adjustment of local physiological response kinetics, introducing a component that influences local somatosensory responses alongside the primary protective and drying functions.

Dosage and Administration Information

How to Use Gepotidacin (Guta): Administration Guidelines

This section describes the administration parameters and schedules for gepotidacin (Guta).

Usage Entity Map

Official Dosage Forms	Approved Administration Routes
Tablets (film-coated)	Oral
Strength: 750 mg

Standard Regimen and Dosing

The approved regimen requires a dose of 1,500 mg per administration, which is equivalent to taking two 750 mg tablets. The medication is administered twice daily (BID), with doses intended to be taken approximately 12 hours apart, structuring a defined 24-hour schedule. The total duration of the treatment course for uncomplicated urinary tract infections is standardized to 5 days.

Conditions of Administration

The tablets must be administered after a meal. Taking the medication after consuming food is a specific instruction provided to minimize the possibility of gastrointestinal intolerance.

Population-Specific Usage

The standard dosage is used for female adults and for pediatric patients who are 12 years of age and older and who weigh at least 40 kilograms. No dosage adjustment is required for individuals with mild or moderate renal or hepatic impairment. However, use of gepotidacin is generally avoided in patients with severe renal impairment (eGFR <30 mL/min) or severe hepatic impairment.

Missed Dose Protocol

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped entirely. Patients must not take a double dose to attempt to compensate for the missed administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Guta (Gepotidacin)

Evidence for Use in Uncomplicated Urinary Tract Infections (uUTI)

Research was predominantly conducted using large Phase 3 randomized controlled trials (RCTs) for uncomplicated urinary tract infections (uUTI), conditions characterized by acute or disruptive episodes. These studies represent a high level of evidence for the endpoints examined and where participants were randomly assigned to receive either Guta or an existing standard antibiotic. The research examined the hypothesis of non-inferiority when Guta was evaluated against standard antibiotic comparator treatments.

The primary outcomes measured included Microbiological Eradication (elimination of the susceptible bacteria) and Clinical Success (monitored patient-reported outcomes describing perceived discomfort). Findings describe patterns observed in the studies relative to the difference permitted by the trial design. The evidence contributes to understanding symptom patterns under the specific, controlled conditions of the clinical trials.

Comparison to Standard Treatments in Studies

The studies were designed to evaluate non-inferiority against active antibiotic treatments, such as existing standard therapies. The research describes that the elimination of bacteria and the patient-reported outcomes were observed in the context of the non-inferiority design. These findings help contextualize how patients reported their experience and provide insight into short-term changes relative to established therapies.

Evidence in Specific Populations

Research focused primarily on female adult patients diagnosed with uUTI. Evidence also includes studies that evaluated a specific subset of pediatric patients, namely those who were 12 years of age and older and met a minimum weight requirement. Consequently, the results apply only to the populations studied, and data for certain groups, such as younger children, remain insufficient.

What is Still Uncertain About the Research for Guta

The current research is narrow, focusing almost exclusively on uncomplicated UTIs. Comparative evidence is lacking for many other types of infections. Also, although initial studies provide robust short-term data, long-term effects are not fully established regarding the durability of the outcomes over many months or years. Limited information exists on this aspect, and ongoing monitoring is required.

Key Studies & References Guideline for the Diagnosis and Treatment of Uncomplicated Urinary Tract Infection

Frequently Asked Questions (FAQ)

Common questions about Guta (FAQ)

Q: Is Guta a type of antibiotic, a pain reliever, or something else?

A: Regulatory documents classify Guta, known by its active ingredient gepotidacin, as a first-in-class triazaacenaphthylene antibacterial. This means it is a type of antibiotic intended to treat specific infections by killing susceptible bacteria.

Q: How quickly does Guta start to act after taking it?

A: Information on the specific onset time for the overall therapeutic effect is not widely published for patients. However, data from clinical studies indicate that measurable concentrations of the drug can be detected in the body relatively quickly after administration.

Q: How long does one dose of Guta typically stay in my system?

A: The duration of the drug in the system is described in the Clinical Pharmacology section of official documents. This information details the terminal half-life of the substance, which indicates the period it is expected to remain active in the body.

Q: Is Guta available over the counter?

A: Official information indicates that Guta is a prescription-only medicine. It can only be obtained with authorization from a licensed healthcare provider.

Q: What is the difference between Guta and [Similar Drug A]?

A: Clinical trials often examine Guta against existing standard treatments using a non-inferiority design to see if it works as well as the other drug. Official sources describe Guta as having a unique, first-in-class mechanism of action that differs from the way many other antibiotics work.

Q: Is Guta known for causing a lot of side effects?

A: Official labeling lists the frequency of common adverse reactions observed in clinical trials, providing a measure of how often certain effects occurred. For example, diarrhea was reported in approximately 16% of patients, and nausea was reported in about 9% of patients in those studies.

Q: Can taking Guta make you feel tired or sleepy?

A: Official safety information includes fatigue (unusual tiredness or weakness) and dizziness as side effects observed in clinical trials. Patients are generally advised to discuss any new or worsening side effects with a healthcare professional.

Q: Is Guta safe for use by older adults?

A: Clinical studies have not identified specific problems in older adults that would limit the use of Guta. However, older patients may be more sensitive to the drug’s effects, particularly if they have age-related changes in kidney or liver function.

Q: Can Guta be used during pregnancy, based on official information?

A: Official documentation states that there are no available data to evaluate the drug-associated risk of Guta use during pregnancy. For this reason, a pregnancy exposure registry is established to collect data and monitor outcomes.

Q: Is Guta cleared to be used while breastfeeding?

A: Official guidance advises patients to inform their healthcare provider if they are breastfeeding or plan to breastfeed. The official documentation advises consultation with a healthcare provider for clarification regarding use during breastfeeding.

Q: Do you need a special kind of prescription to get Guta?

A: Guta is classified as a prescription-only medicine. This means it can only be obtained with a valid prescription from a licensed healthcare provider.

Q: How is Guta usually packaged?

A: Guta is supplied as a yellow, film-coated tablet containing 750 mg of the active ingredient gepotidacin. The exact packaging size and quantity are determined by the authorized prescription.

Q: Why might a doctor prescribe Guta instead of another medicine?

A: Research supports its use as an effective alternative to existing standard therapies. Its unique mechanism of action and activity against certain drug-resistant organisms are points of difference noted in regulatory contexts.

Q: Is Guta considered a first-line treatment for the condition it addresses?

A: Guta is described in regulatory materials as a valuable alternative to existing first-line therapies for uncomplicated urinary tract infections. This positioning is often for patients with resistance or intolerance to other agents.

Q: Are there any warnings about driving or operating machinery while on Guta?

A: Because side effects such as dizziness, blurred vision, and presyncope (feeling faint) have been reported, patients are generally advised to be aware of how the medicine affects them before driving or operating heavy machinery.

Q: Can Guta affect my mood or energy levels?

A: The official safety information includes fatigue (unusual tiredness or weakness), which relates to energy levels, as a potential side effect observed in clinical trials. Information on direct effects on mood is not generally specified in the official adverse events listings.

Q: Are there specific instructions for stopping the use of Guta?

A: The official recommendation is to continue taking Guta for the full 5-day treatment course as prescribed, even if symptoms begin to improve quickly. The full treatment course should be completed, as stopping early may not fully clear the infection.

Q: Does Guta have any known major allergic reaction risks?

A: Hypersensitivity reactions are listed in the official safety documents. These reactions include the risk of anaphylaxis, which is a severe allergic reaction. Severe allergic reactions are considered medical emergencies.

Q: What does official guidance say about taking Guta before surgery?

A: Official information advises patients to inform their doctor or dentist that they are taking Guta before having any type of surgery, including dental surgery. This allows the healthcare team to be aware of all current medications prior to the procedure.

Q: What if I accidentally take two doses of Guta close together?

A: If more than the recommended dose is taken, official documents describe potential symptoms of overdose, such as fast, pounding, or uneven heartbeat, which may be of concern.

Q: Is there a Black Box Warning associated with Guta, according to the FDA?

A: Official labeling includes a major warning regarding QTc prolongation, which is a dose and concentration-dependent change in heart rhythm. This type of serious safety concern is addressed prominently in the Warnings and Precautions section.

Q: What does official research evidence say about Guta?

A: The main evidence comes from large Phase 3 trials that evaluated Guta against an active comparator. These studies focused on achieving microbiological eradication (killing the bacteria) and clinical success (resolution of patient-reported discomfort) for the condition it is approved to treat.

Q: Are there any long-term studies available for Guta?

A: Current research provides robust short-term data from clinical trials. However, official documents state that long-term effects regarding the durability of the outcomes over many months or years are not fully established at this time.

Q: What if I take Guta and it doesn't seem to be working?

A: Official usage recommendations state that Guta should be used only for infections proven or strongly suspected to be caused by susceptible bacteria. The prescribing healthcare provider should be consulted with any concerns regarding the effectiveness of the treatment.

Q: Is Guta known to cause stomach problems?

A: Gastrointestinal issues are among the most common adverse events reported in clinical trials. These effects can include symptoms such as diarrhea, nausea, and abdominal discomfort.

Q: What is the general long-term outlook for people using Guta?

A: Guta is prescribed as a short-term, 5-day course of treatment for specific infections. As an antibiotic, the goal of Guta is to address the acute infection. The long-term durability of the outcome is an area that continues to be monitored in regulatory contexts.

Q: Is Guta meant for short-term or long-term use?

A: The approved regimen for uncomplicated urinary tract infections is a standardized 5-day treatment course. This indicates Guta is intended for short-term, acute use rather than long-term maintenance therapy.

Q: Does Guta help with inflammation?

A: The official mechanism of action includes a component that influences local physiological responses. This is described as modulating the transcription of pro-inflammatory mediators, suggesting an influence on localized inflammation.

Q: What is the main benefit Guta is supposed to deliver?

A: The primary clinical benefit evaluated in studies is achieving microbiological eradication (elimination of susceptible bacteria) and clinical success (resolution of patient-reported discomfort) for the condition it is approved to treat.

How should Guta be stored and disposed of?

How to Store and Dispose of Guta?

The storage and disposal of Guta (gepotidacin) tablets must adhere to official regulatory requirements to ensure product stability and safety.

Storage Requirements

Guta must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory to keep the tablets protected from moisture and excess heat; the medicine must not be stored above 30°C and should not freeze. To maintain stability, Guta must remain in the original container and be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Guta must be disposed of in accordance with local regulations. The official disposal protocol advises using a medicine take-back program if one is available. It is strictly required that the tablets not be thrown away via wastewater (such as flushing) or general household trash.

Guta